17 June 2016
Redx Pharma is pleased to announce that it will present data on its novel bacterial topoisomerase inhibitors (NBTIs) at the inaugural annual American Society for Microbiology (ASM) Microbe 2016 conference taking place from 16-20 June in Boston, Massachusetts.
Both the rise of antimicrobial resistance and the current antibiotic innovation gap have highlighted the need for novel antimicrobial agents, particularly for the treatment of Gram-negative bacterial infections. Redx is making promising progress in meeting this need following its discovery of a series of NBTIs that demonstrate broad-spectrum antibacterial activity against ESKAPE pathogens and low potential for resistance development.
Redx will be presenting the in vitro biological properties of its NBTIs, including activity against multi-drug resistant strains, preliminary assessment of safety profile and data on the in vivo exposure level of representative compounds.
No price-sensitive information will be provided during the presentation. A poster containing the relevant information will be made available on the Redx website following the presentation.